BillionToOne Appoints Anthony Pagano to Board, Enhancing Financial Leadership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Board Enhancement: BillionToOne announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026, bringing extensive experience in driving financial performance and strategic growth from his current role as CFO of Genmab.
- Financial Leadership: During Pagano's tenure at Genmab since March 2020, the company's annual revenue surged from $100 million to over $3 billion, demonstrating his capability in guiding high-growth life sciences companies.
- Professional Background: Prior to Genmab, Pagano served as Corporate Controller at NovaDel Pharma and provided audit and M&A consulting services at KPMG LLP, showcasing his strong foundation in finance and strategic planning.
- Future Outlook: BillionToOne CEO Dr. Oguzhan Atay stated that Pagano's appointment will significantly strengthen the Board's financial expertise, supporting the company's next phase of growth in the molecular diagnostics sector.
Analyst Views on BLLN
Wall Street analysts forecast BLLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLLN is 137.83 USD with a low forecast of 110.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 94.720
Low
110.00
Averages
137.83
High
160.00
Current: 94.720
Low
110.00
Averages
137.83
High
160.00
No data
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
